chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After October, I have developed an itching and hives that progressed with using superficial antibiotics. About three weeks ago it started creeping up my legs. I put my self on Benadryl, it slowed it down to my lower extremities to my ankle and legs. I went to see a dermatologist, and her told me I was getting psoriasis. I have never had this; I had changed my laundry detergent. This basically cleared up things. It under extremely under control with triamcinolone, every other day. It is contained, not cured.
Case number PHEH2015US019625, is an initial spontaneous report received from a healthcare professional on 01 Oct 2015 and with follow-up information from healthcare professional on 01 Oct 2015. This report refers to a 42 year old female patient. Historical condition and concomitant medication were not reported. The patient was vaccinated with FLUVIRIN (batch number: 1516101, expiry date: Jun 2016) intramuscularly at a dose of 0.5 ml on 30 Sep 2015. It was reported that the unopened Multi Dose Vials (MDVs) were placed in a refrigerator and few of them were frozen (14 out of 35 vials). However, they had other vaccines which did not freeze. Vaccine was administered from one of those MDVs which were not freeze. No adverse event was reported. Follow up information received from the health care professional on 01 Oct 2015: Expiry date of suspect vaccine updated.
1726-Vaccinated  1734-C/o dizziness, flushing, lightheadedness, sweating, palpitation, anxious/jittery, sleepy, tingling-tongue. 1820 c/o chest tightening. Patient refused Epi. Benadryl 50 mg/IM given, Patient was transferred to ER.
After about 15 minutes patient said lightheadedness just came over her from out of no where.  She felt like she might pass out but did not.  She was given a cold compress and bottle of water.  She felt better and no longer felt like passing out but still felt lightheaded so she had someone come pick her up so she was not driving.
After vaccine Fri 12/25, Sat 12/26, Sun 12/27 had pain at injection site and went away.  12/26/2020; injection site start feeling itchy, bumpy, redness and a little bit of pain.  Today its better.
Extreme body shivers and temperature fluctuations for a 14 hour period, starting at 5pm the day after the vaccination r
?Covid Arm?: injection site redness, soreness, swelling, hot to the touch, painful to the touch, itching. Arm redness is in an area about 4 inches vertically and 7 inches horizontally.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 014M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Mar-2021 at 10:33 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 30-Mar-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. In March 2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 68.40 and 68.47  No concomitant medications were reported.  Batch number 019B21A administered on 30-Mar-2021 with temperature 33 at 09:00 AM. This vial was moved to fridge on 23-Mar-2021 and beyond use date for the vial was reported as 22-Apr-2021. Product moved to clinic on 30-Mar-2021.  Batch number 014M20A administered on 02-Mar-2021 with temperature 27 at 09:00 AM, 29 at 10.00AM, 32 at 11.00 AM, 33 at 12.00 PM, 35 at 02.00 PM, 26 at 3.00 PM . This vial was moved to fridge on 24-Feb-2021 and beyond use date for the vial was reported as 26-Mar-2021. Product moved to clinic on 02-Mar-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour.  No treatment medications were reported.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 08-JUN-2012, the patient was inoculated with ZOSTAVAX by a physician as recommended for routine adult health maintenance for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended and the patient subsequently contracted a persistent strain condition of herpes zoster. On or about 17-DEC-2013, the patient was treated the same physician for a blistering vesicular outbreak which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
really bad headache; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (really bad headache) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 610M20A) for COVID-19 vaccination.     The patient's past medical history included Breast cancer (17 years ago but has not had any problems since then). Concurrent medical conditions included Myelodysplasia and Osteopenia.    On 06-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, the patient experienced MIGRAINE (really bad headache). The patient was treated with IBUPROFEN (ADVIL 12 HOUR) for Adverse event, at a dose of 1 dosage form and PARACETAMOL (TYLENOL) for Adverse event, at a dose of 1 UNK. At the time of the report, MIGRAINE (really bad headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported. The patient was talking to a friend who had been having neurological problems with double vision, and headaches after receiving the  vaccine. The patient also spoke to someone else, whose sister had very bad vertigo since receiving the vaccine, and had episodes of vertigo in the past but since receiving the vaccine, it had been serious.   This case was linked to MOD-2021-281277 (Patient Link).
ARM was hurting  for 3 weeks, blisters on the upper arm vaccine area, rash on the entire right arm, full torso and and both legs, short of breath, shivers, fever and body ache for 2 weeks. This lasted from March 10th through March 20th
Expired dose was administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 15-month-old female patient who received DTPa (Infanrix) (batch number 49tm3, expiry date 28th May 2022) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 10th June 2022, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 10th June 2022, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 10-JUN-2022 Reporter's Comments: The medical assistance reported that the patient received expired dose of infanrix. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. Additional Supportive Information: The patient received expired infanrix, which led to expired vaccine used.
Constant low grade fever (30+ days), soreness in arm, muscle aches all over, itchy injection site, nauseas, tired, constant headache; 60 days later, subarachnoid hemorrhage, severe all-over head pain, constant fast heart rate, no energy, constant memory recall/lapses, fogginess, and currently still experiencing...
Generalized tonic/clonic febrile seizure with fever on 11/21/01 and a 10-15 second seizure with 3 hours of decreased activity. Evaluated in ER. Had a rash develope late on 11/22/01 for 2 days. No residual effects noted to date.
Left artm with area of hardness + redness extending from injection site - total size of rxm approx greater than the size of 4 quarters.  Patient's mom reports patient has been scratching site.
Pentacel vaccine was given and was not mixed so the patient only got the liquid portion with no reported adverse event; Pentacel vaccine was given and was not mixed so the patient only got the liquid portion with no reported adverse event; Initial information was received on 22-Sep-2022 regarding an unsolicited valid  non-serious case received from an other health professional.  This case involves a 10 months old male patient who experienced pentacel vaccine was given and was not mixed so the patient only got the liquid portion with no reported adverse event while receiving vaccine DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 13V (CRM197) (PREVNAR 13) for Immunization.  On 16-Sep-2022, the patient received 0.5 ml of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (lot UJ673AAA and expiry 30-Apr-23) (formulation and strength: unknown) via intramuscular route in the left thigh for Immunization .  On 16-SEP-2022 the patient developed a non-serious pentacel vaccine was given and was not mixed so the patient only got the liquid portion with no reported adverse event (Product preparation issue) (Single component of a two-component product administered)  (latency same day) following the administration of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE.  Action taken with DIPHTHERIA, TETANUS, AC PERTUSSIS, IPV AND HIB VACCINE (PENTACEL) was not applicable.  At time of reporting, the outcome was Unknown for the event pentacel vaccine was given and was not mixed so the patient only got the liquid portion with no reported adverse event and was unknown for the event pentacel vaccine was given and was not mixed so the patient only got the liquid portion with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Patient reported initial pain in the arm. She stated that 4 days later she experienced "severe heartburn".
9/22/21 He went to hospital for Low O2 and is currently admitted.  Patient is fully vaccinated.
Information has been received from a physician concerning an approximately 25 year old male patient who is a medical student and was vaccinated on 21-SEP-2007 with VARIVAX (Lot #655065/1142F, expiration date 28-SEP-2008).  On 23- or 24-SEP-2007, the patient telephoned the physician and reported that he had developed a sore throat and eye redness.  Initially, it was reported that the patient developed symptoms 10-11 days after receiving VARIVAX.  The patient was hospitalized with a mild-to-moderate case of Stevens-Johnson syndrome.  The physician reported that the patient had fully recovered.  There was no product quality complaint.  Upon internal review Stevens-Johnson syndrome was determined to be an other important medical event.  Additional information has been requested.
no symptomatic side effects; VAQTA that was inadvertently administered after it's expiration date; This non-valid spontaneous report was received from a certified medical assistant and refers to a patient of unknown age ad gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 13-MAR-2023, the patient was inadvertently administered with an expired dose of hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, lot #W007375, expiration date: 16-JAN-2023 (expired product administered), administered for prophylaxis (dose, and route of administration were not provided). The vaccine had not experienced any temperature excursions and no symptomatic side effects were reported for the patient.  This report is non-valid due to lack of the patient's identifiers.  Follow up information recived on 07-APR-2023:  This spontanous report refers to 19-month-old male patient.The patient identifiers were provided. Vaccine administrator was provided.  Tis is one of the several cases recived from the same reporter.
Flu-like symptoms; This spontaneous case was reported by a non-health professional (subsequently medically confirmed) and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for an unreported indication: LENVIMA (Patient was not currently taking Lenvima 12 mg at the moment and reported that she went to the ER for chest pain and increased blood pressure on 15 Feb 2021, healthcare suspected that it was caused by Lenvima and put her on a hold. Due to the event caused by vaccination and her healthcare provider decided to keep her off of Lenvima for a little while longer.) on 16-Jan-2021. Concurrent medical conditions included Endometrial cancer (Endometrial Cancer C54.1). Concomitant products included PEMBROLIZUMAB (KEYTRUDA) for an unknown indication.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Mar-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms). At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms) outcome was unknown. Not Provided          Plan was to have a CT scan today (18 Mar 2021)  and possibly resume lenvatinib mesilate at a lower dosage on 23 Mar 2021. No treatment information was provided.Her healthcare provider decided to keep her off of  lenvatinib mesilate for a little while longer due to the event caused by vaccination. Action taken with mRNA-1273 in response to the events was not applicable.   Reporter did not allow further contact
Dizziness lasting more than a day; very migraine like; slight nausea; light sensitivity; visual disturbances; This is a spontaneous report from a contactable consumer who reported for herself. A 73-year-old female patient received her first single dose of BNT162B2 (Pfizer-BioNTech Covid-19 vaccine, lot number EL8982) at left arm 04:00 PM on 25Jan2021 for Covid-19 immunization. The patient's medical history included diabetes, osteopenia, hematuria, irritable bowel syndrome (IBS), high cholesterol, migraine. The patient had known allergies to penicillin- diarrhea, lactose intolerant, extreme allergy to sesame seeds and sage family. Concomitant medications included cyanocobalamin (B12), metformin, levothyroxine, multi vit, and calcium. The patient had not received other vaccines within four weeks. Around 10:15 AM on 26Jan2021, the patient experienced dizziness which lasted more than a day, light sensitivity, visual disturbances, slight nausea- very migraine like. No treatment was received for the events. The outcome of the events was resolving at the time of reporting. The patient had no Covid prior vaccination and had not covid tested post vaccination.
WORST MUSCLE ACHES; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 12-AUG-2021 for prophylactic vaccination. Batch number was not reported and has been requested. No concomitant medications were reported. On 12-AUG-2021, the patient experienced worst muscle aches. Treatment medications (dates unspecified) included: cyclobenzaprine hydrochloride, paracetamol, and ibuprofen. The action taken with covid-19 vaccine was not applicable. The patient had not recovered from worst muscle aches. This report was non-serious.
pt recvd vax & exp deep ache,bone ache,pain @ inj site,& warmth to touch (inj site);sx persist
9 year old son (fully vaccinated a month ago) given Pfizer vaccine again by mistake by the pharmacy.  No adverse reactions yet, monitoring but definitely a vaccination error.
Later in evening after vaccine administration: fever, chills, headache, nausea/vomting, body aches, exhaustion, facial swelling, rash on face and head. Unaable to sleep all night
high fever (103.7), shivering, skin appeared blue on arms, legs, face;
covid vaccine breakthrough case  dose 1 Pfizer 2/24/21 EN6198 dose 2 Pfizer 3/17/21 EN6205
Nursing home requested patient receive COVID vaccine.  We gave Pfizer first dose and upon entering into links discovered patient received Moderna vaccines on 1/20/21 and 4/27/21.  Patient signed consent to receive vaccine and had not adverse reaction during time period observed post vaccination.
fever-t104 APAP given, prolonged crying; extreme ? lt arm; to ER for exam;
9/19/17 9:50 Patient received MENACTRA vaccine in right thigh. Patient rested briefly in office before leaving with mother. Mother returned to office 15 minutes later. Mother states that patient passed out in vehicle 10 minutes after getting vaccine. Patient was evaluated by ARNP.
patient developed hives and swollen lips after her vaccine. we administered 50 mg liquid benadryl and monitored, her symptoms resolved.
hx 3rd & 4th day following 1st DTP inject 14JAN92 fever cont to rise to 105; pt broke w/rash, crying unconsolable;  pt given DPH;
Information has been received from a pharmacist concerning two male patients who on 17-JUN-2009 were subcutaneously vaccinated with PNEUMOVAX. Subsequently the patients developed cellulitis in the injection arm. The patients were seen on 20-JUN-2009 and the diagnosis was confirmed. The patients were not recovered at the time of reporting. Follow-up information was received from the pharmacist. The pharmacist provided the lot number 662840/1577X but clearly stated that after talking to her supervisor, the name of the patient would not be provided. This is one of several reports from the same source. No further information was available.
8/24/22 presents to EC ED for "elevated creatinine all". PMHx of "pancreatic adenocarcinoma with peritoneal carcinomatosis s/p loop colostomy, on chemotherapy, obstructive uropathy s/p bilateral ureteral stents, left PCN placement, CAD, emphysema, pulmonary nodule, hypertension, hyperlipidemia"
Onset of wheal and flare type erythematous reaction in left upper arm around injection site, pruritus with onset 3/29. Resolved 4/3/13.
Chronic ache in muscles and bones on the left side of the body- especially the left ankle.  The pain is chronic and constant.  Cold aggravates it.  Some intermittent achy-ness in the right ankle.  Body wide joint stiffness and intermittent joint pain-especially in the hips.  Fatigue and tiredness during the day.  These issues began directly after having the vaccines.  No prior history of these problems.
woke up 9 aug2021, coughed all night , different from usual, no temperature. Did covid test and was positive. I coughed and got weaker. Called doctor on Tuesday, got antibiotics, Pt wanted infusions. On wed, I could barely function. Went to ER. Infusion on the 8th of having covid.  Now tested negative and still not well.
The day of vaccination I got chills, body aches, and fever along with tiredness and bruises. The next 2 days also had tiredness. Every day since I got the shot I've had bruises and leg pains. I continue to have the bruises and leg pains.
3rd dose administered in error as EMR immunizations were not updated  when old records were scanned in and not abstracted which lead MA to believe this vaccine was necessary.  Parent reports on 8/11 site of vaccine was firm, swollen and hot to touch and child had temp of 100.4.  care advise was discussed by Triage RN.
Received vaccination on last dose 01/29/2022, baby was born at 5lbs 5oz.  My blood pressure rose after getting the vaccine, causing me to have to be induced.  After the vaccine I have had sever migraines/headaches, and inflammation. I have no history of high blood pressure or migraines or inflammation.  I am still experiencing high blood pressure, migraines, and inflammation(achy bones and organs) all of which I need medication for.
SEBORRHEIC DERMATITIS; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1822811 expiry: UNKNOWN) dose was not reported, administered on 12-OCT-2021 for covid-19 prophylaxis. No concomitant medications were reported. On DEC-2021, the patient experienced seborrheic dermatitis. On SEP-2022, Laboratory data included: Biopsy seborrheic dermatitis. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from seborrheic dermatitis. This report was non-serious.
pt recv vax 3NOV97 & 1DEC97 pt c/ lt upper arm pain;stated it had come on p/vax & had worsened since that time;@ that time pt felt to have a deltoid tendonitis;pt put on med;pt still having deltoid tendonitis & pain under acromion;
Same night had chills and fatigue, next morning hot/sweaty for hours, sore arm better by Sunday night. Mon/Tues itchy throat with random dry cough, if try to hold back watery eyes and/or runny nose. Wednesday red patches hives on face/neck.